Depression and anxiety are on the rise but front-line treatments aren’t always effective. Explore emerging approaches to mental health care including transcranial magnetic stimulation, psilocybin and ketamine, and separate science from hype.
Dr. Jeffrey Eisen, MD, MBA is an Assistant Clinical Professor of Psychiatry at Oregon Health and Science University, an Adjunct Clinical Instructor of Psychiatry at Harvard Medical School’s Cambridge Health Alliance, and the Chief Medical and Health Integration Officer of Cascadia Behavioral Healthcare, the largest provider of community-based mental health and substance use treatment services in the state of Oregon. Prior to these appointments, Dr. Eisen served as a full-time faculty member in the Department of Psychiatry at Harvard Medical School, and as the Medical Director for Community Behavioral Health Services at Beth Israel – Lahey Health, one of Massachusetts’ largest healthcare providers. His team at Lahey Health designed innovative programs for improved health equity for patients with co-occurring medical, psychiatric, and addictions diagnoses. He has presented nationally on such topics as behavioral health centered integrated care, as well as population health and data analytics approaches for the behavioral health field. He currently sits on the mental health advisory team and the opioid overdose epidemic task force for Oregon Governor Kate Brown.
Dr. Eisen can be reached at: firstname.lastname@example.org
Dr. Jonathan Horey, MD is board-certified in adult psychiatry and addiction medicine and is the co-founder and Chief Medical Officer of Active Recovery TMS. Dr. Horey completed medical school and psychiatry residency at Columbia University in New York City where he served as Chief Resident. After residency, he remained at Columbia as an Assistant Clinical Professor of Psychiatry and the Medical Director of Substance Abuse Services at the Columbia Doctors 51st Street clinic. During his time at Columbia, Dr. Horey became familiar with transcranial magnetic stimulation (TMS) while treating patients undergoing the procedure and from colleagues in the Brain Stimulation division at Columbia who were involved in some of the early clinical TMS studies. After moving back to his hometown of Portland, OR in 2013, he was a staff psychiatrist at Betty Ford-Hazelden Springbrook before taking the position of Chief Medical Officer at Sunspire Health, a national group of residential addiction treatment centers. Dr. Horey has maintained a private practice in Portland since 2014 and co-founded Active Recovery TMS in 2017 after discovering a lack of accessible TMS treatment in Portland for his patients with treatment-resistant depression. He has lectured widely on addiction medicine as well as on TMS and is an advanced candidate in psychoanalysis at the Oregon Psychoanalytic Institute. Now with three locations across the Portland metro area, Active Recovery TMS will be expanding to a fourth location in Salem in August 2020.
Dr. Horey can be reached at: email@example.com
Dr. Sandhya Prashad, MD is a board certified psychiatrist and is the founder and medical director of Houston Ketamine Therapeutics and Houston TMS Therapeutics. Dr. Prashad completed both medical school and residency training at Baylor College of Medicine in Houston, Texas. She completed her undergraduate training at the University of Texas in Austin. During her residency training, she served as the administrative chief resident as well as the chief resident of the Baylor Psychiatry Clinic. She has a special interest in treating depression and bipolar disorder, especially those that are treatment resistant. During her residency training, she focused on evaluating and treating treatment resistant mood disorders at the Baylor Mood Disorders Center. Dr. Prashad has been in private practice in the Houston area since 2011. She has been administrating IV Ketamine in her practice since 2016 and is also a founding member, the former secretary and the current president of the American Society of Ketamine Physicians. She also utilizes deep TMS and esketamine in her practice for treating treatment resistant disorders. Dr. Prashad is also actively involved in providing awareness and education to other physicians and the public regarding the benefits of ketamine therapy. She has also presented on the national level at several medical conferences regarding the use of ketamine. In addition, she has served on advisory panels for research related to ketamine.
Dr. Prashad can be reached at: Sandhya@sprashadmd.com
Dr. Anthony Bossis, Ph.D. is a clinical psychologist and clinical assistant professor of psychiatry at NYU School of Medicine who since 2009, has been conducting FDA-approved psychedelic research investigating the therapeutic effects of psilocybin, a naturally occurring compound found in specific species of mushrooms. Dr. Bossis was director of palliative care research, co-principal investigator, and a session guide for a landmark clinical trial that demonstrated a significant reduction in depression and anxiety from a single psilocybin-generated mystical experience in persons with cancer. Subjective features of a psilocybin-generated mystical experience include unity, sacredness, transcendence, and a greater connection to deeply felt positive emotions including that of love. Implications for the scientific study of psilocybin and mystical experience include the alleviation of end-of-life emotional distress, enhanced psychological well-being, treatment of myriad mental health disorders, and a deeper understanding for the study of meaning and spirituality. Dr. Bossis is a clinical supervisor of psychotherapy training and the co-founder and former co-director of the Palliative Care Service at Bellevue Hospital. He maintains a private psychotherapy practice in NYC.
Dr. Bossis can be reached at: Anthony.Bossis@nyulangone.org
Dane Fickes is a behavioral health pharmacist and site manager at a Genoa Healthcare pharmacy located onsite at a community mental health center in Medford, Oregon. He earned a Doctor of Pharmacy degree from St. Louis College of Pharmacy in 2018 and completed a master’s in business this year. His interests include developing new methods of integrating behavioral health care between providers and pharmacy. While at Genoa Healthcare, Dane instituted a program to administer long acting injectable antipsychotics (LAIAs) to clients and developed a transition-of-care program with the regional hospital’s behavioral health unit to supply and administer discharge medications and LAIAs.
Dane Fickes can be reached at: DFickes@genoahealthcare.com